A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 122
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DF
Long Form : desferrioxamine
No. Year Title Co-occurring Abbreviation
1965 [DESFERRIOXAMINE (DF) AND DIETHYLENE TRIAMINE PENTA-ACETIC ACID TRISODIUM CALCIUM SALT (CA DTPA NA3) IN SIDEROSIS. 2]. ---
1975 Desferrioxamine B: reversible side effects of high daily doses. WBC
1976 Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. ---
1977 Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. ---
1978 Determinants of fecal and urinary iron excretion in desferrioxamine-treated rats. DTPA
1978 Prevention of iron loading in transfusion-dependent thalassaemia. IM, s.c
1979 Rhodotorulic acid--investigation of its potential as an iron-chelating drug. RA
1981 Anemia of inflammatory disease in the dog: availability of storage iron in inflammatory disease. ---
1981 Continuous intra-venous (CIV) infusion of desferrioxamine (DF) in a hemodialysed patient with transfusion siderosis. CIV
10  1981 Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload. ---
11  1981 Liposome-encapsulated desferrioxamine in experimental iron overload. 59Fe-DRBC, GC, ML, UL
12  1981 Synergistic effect of nitrilotriacetate on iron mobilization by desferrioxamine in vivo. NTA
13  1982 67 Ga-labeled human fibrinogen: a new promising thrombus imaging agent. ---
14  1982 Deferoxamine, a promising bifunctional chelating agent for labeling proteins with gallium: Ga-67 DF-HSA: concise communication. HSA
15  1982 Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome. i.v, s.c, Vit C
16  1982 Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug. EHPG
17  1982 Hepatocyte iron kinetics in the rat explored with an iron chelator. ---
18  1982 Plasmodium falciparum: inhibition of in vitro growth by desferrioxamine. ---
19  1982 Simple assay for urinary iron after desferrioxamine therapy. ---
20  1982 [Chelating therapy in beta-thalassemia]. ---
21  1982 [Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major]. TQ
22  1983 Enhanced iron removal from liver parenchymal cells in experimental iron overload: liposome encapsulation of HBED and phenobarbital administration. HBED
23  1983 Syntheses of iron bis(pyridoxal isonicotinoylhydrazone)s and the in vivo iron-removal properties of some pyridoxal derivatives. PINH
24  1983 [Inhibition of heme biosynthesis in erythroid precursors (BFU-e) isolated from human peripheral blood: effects on globin synthesis]. ---
25  1984 Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion in idiopathic hemochromatosis. IH, UIE
26  1985 Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization. ---
27  1985 Failure of desferrioxamine to modify the toxicity of paraquat in rats. ---
28  1985 In vivo kinetics and thrombus accumulation of 67Ga-labeled urokinase. ---
29  1985 Preparation of 67Ga-labelled human IgG and its Fab fragments using desferoxamine as chelating agent. ---
30  1986 Desferoxamine blocks IL 2 receptor expression on human T lymphocytes. MNC
31  1986 Effect of desferrioxamine on the development of hexachlorobenzene-induced porphyria. ALA-S, HCB, PCL, PCL
32  1986 Non-ferritin, non-heme iron pools in rat tissues. LMW
33  1987 Antioxidant capacity of desferrioxamine in biological systems. ---
34  1987 Desferrioxamine suppresses Plasmodium falciparum in Aotus monkeys. ---
35  1987 [Evaluation of deferoxamine capacity to revert a severe porphyria induced by hexachlorobenzene]. HCB
36  1988 Antioxidant capacity of desferrioxamine and ferrioxamine in the chemically-initiated lipid peroxidation of rat erythrocyte ghost membranes. ---
37  1988 Deferoxamine inhibition of malaria is independent of host iron status. ---
38  1988 Deferoxamine-induced growth retardation in patients with thalassemia major. ---
39  1988 Expression of the haemopexin-transport system in cultured mouse hepatoma cells. Links between haemopexin and iron metabolism. Hepa, MHBP
40  1988 Induction to erythroid differentiation of K562 cells by 1-beta-D-arabinofuranosylcytosine is inhibited by iron chelators: reversion by treatment with hemin. ara-C
41  1988 Iron-chelating therapy. ---
42  1989 Continuous intravenous infusion of deferoxamine reduces mortality by paraquat in vitamin E-deficient rats. ---
43  1990 Iron chelation. ---
44  1990 Iron-mediated radical reactions upon reperfusion contribute to myocardial "stunning". PBN
45  1990 L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. UIE
46  1990 Mechanism of protection of alveolar type II cells against paraquat-induced cytotoxicity by deferoxamine. PBH
47  1990 Stage-dependent effect of deferoxamine on growth of Plasmodium falciparum in vitro. ---
48  1990 Stress initiated during isolation of rat renal proximal tubules limits in vitro survival. LDH-R, TBA
49  1991 Ferrioxamine B derivatives as hepatobiliary contrast agents for magnetic resonance imaging. MRI
50  1991 Hydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. ADP
51  1992 Allylamine toxicity in embryonic myocardial myocyte reaggregate cultures: The role of extracellular metabolism by benzylamine oxidase. AA, ACR, BZO, MESNA, MMR
52  1992 Deferoxamine effect on selenite-induced cataract formation in rats. PSC
53  1992 Effect of iron chelators on paraquat toxicity in rats and alveolar type II cells. CP51
54  1992 Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function. Con A, CP, IL-2
55  1992 Gallium-labeled deferoxamine-galactosyl-neoglycoalbumin: a radiopharmaceutical for regional measurement of hepatic receptor biochemistry. DF-NGA, NGA
56  1992 Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores. RE
57  1992 The antimalarial effect of iron chelators: studies in animal models and in humans with mild falciparum malaria. ---
58  1993 Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. LDH, MDA
59  1993 Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals. DTPA
60  1993 Desferrioxamine and urinary zinc excretion in beta-thalassemia major. ---
61  1993 Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury. ---
62  1993 Lethal photosensitization by endogenous porphyrins of PAM cells--modification by desferrioxamine. ALA
63  1993 Possible involvement of active oxygen species in selenite toxicity in isolated rat hepatocytes. DFMn, LDH, SOD, TBA-RS
64  1993 Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases. ---
65  1993 Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients. HBT
66  1994 Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. ---
67  1994 Deferoxamine given at reperfusion improves function of the cold-stored rat heart. KHB
68  1994 Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. ---
69  1994 Effect of long-term removal of iron from asbestos by desferrioxamine B on subsequent mobilization by other chelators and induction of DNA single-strand breaks. SSBs
70  1994 Free radical modes of cytotoxicity of adriamycin and streptonigrin. ADR, dsb, STN, TP
71  1994 Regulation of protein kinase C (PKC) expression by iron: effect of different iron compounds on PKC-beta and PKC-alpha gene expression and role of the 5'-flanking region of the PKC-beta gene in the response to ferric transferrin. FAC, FeLF, FeTF, PKC
72  1995 Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. ALA, BCCs, PDT
73  1995 Regulation of ferritin expression by alcohol in a human hepatoblastoma cell line and in rat hepatocyte cultures. ---
74  1996 Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia. ALDA, HIF-1, PGK-1, VEGF
75  1996 Applicability of short-lived radiometallic nuclide for high sensitivity two-site "sandwich" immunoradiometric assay: human growth hormone assay. 67Ga, hGH, SA
76  1996 Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor imaging. ---
77  1997 An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients. ---
78  1997 Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. DTPA
79  1997 Flow cytometric assessment of hydroxypyridinone iron chelators on in vitro growth of drug-resistant malaria. FCM, MIC
80  1997 IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture. DRBCs, RE
81  1998 Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. ---
82  1998 Role of H2O2 and heme-containing O2 sensors in hypoxic regulation of tyrosine hydroxylase gene expression. DCF, TH
83  1999 Hemoglobin toxicity in experimental bacterial peritonitis is due to production of reactive oxygen species. DMPO, Hb
84  1999 Long-term follow-up of skeletal dysplasia in thalassaemia major. TM
85  1999 Noninvasive evaluation of in vivo free radical reactions catalyzed by iron using in vivo ESR spectroscopy. ESR
86  2000 Effect of Desferrioxamine on Silica-Induced Pulmonary Reaction. IL-8, MDA, TNF-alpha
87  2000 Possible protective effect of melatonin and/or desferrioxamine against streptozotocin-induced hyperglycaemia in mice. CHO, MDA, MLT, STZ, TG
88  2000 Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). ---
89  2001 A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate. CDKI
90  2001 Expression of multiple genes regulating cell cycle and apoptosis in differentiating hematopoietic cells is dependent on iron. PMA
91  2002 Differentiation of functional dendritic cells and macrophages from human peripheral blood monocyte precursors is dependent on expression of p21 (WAF1/CIP1) and requires iron. DCs, GM-CSF
92  2002 Human immunodeficiency virus type 1 replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis. EMSA, HIV-1, NF, PBL
93  2002 Melatonin improves deferoxamine antioxidant activity in protecting against lipid peroxidation caused by hydrogen peroxide in rat brain homogenates. 4-HDA, MDA
94  2002 Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients. ---
95  2003 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. cmAb, mAbs
96  2004 Molecular shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum. AD, AS, FG
97  2005 Deferoxamine photosensitizes cancer cells in vitro. ALA, PpIX
98  2005 Effect of neonatal body temperature on postanoxic, potentially neurotoxic iron accumulation in the rat brain. ---
99  2005 Myeloperoxidase activity imaging using (67)Ga labeled substrate. CT, DCC, MPO, SPECT
100  2006 Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. MRI, TM
101  2007 Iron studies in infants born to an iron overloaded mother with beta-thalassemia major: possible effects of maternal desferrioxamine therapy. SI/TIBC
102  2007 Topical applications of iron chelators in photosensitization. DMSA, EDTA, PpIX, ROS, UV
103  2009 Comparative mutagenic effects of structurally similar flavonoids quercetin and taxifolin on tester strains Salmonella typhimurium TA102 and Escherichia coli WP-2 uvrA. CAT, EDTA, NGS, QT, SOD, TF
104  2010 Iron chelation prevents lung injury after major hepatectomy. PAF-AcH, SOD
105  2010 Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Df-Chx-Mal, Df-Iac, PET
106  2012 Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. ---
107  2013 Protective Role of Silymarin and Deferoxamine Against Iron Dextran-induced Renal Iron Deposition in Male Rats. BUN, Cr, KID, SM
108  2014 Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model. SM
109  2014 Gallium-68-labeled anti-HER2 single-chain Fv fragment: development and in vivo monitoring of HER2 expression. Ga-68, HER2, PET, scFv
110  2014 Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography. huCD20TM, NHL, PET
111  2015 Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in beta-Thalassemic Mice. ---
112  2015 The Effects of Medicago Sativa and Allium Porrum on Iron Overload in Rats. SI, TIBC
113  2015 ⁸⁹Zr-Labeled Versus ⁴I-Labeled alphaHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo. ---
114  2016 Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging. PET, uPA
115  2016 CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. HCC, NIRF, PET, s.c
116  2016 Deferoxamine improves antioxidative protection in the brain of neonatal rats: The role of anoxia and body temperature. ---
117  2016 Deferoxamine prevents cerebral glutathione and vitamin E depletions in asphyxiated neonatal rats: role of body temperature. ---
118  2016 ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors. mAb
119  2017 CD38 as a PET Imaging Target in Lung Cancer. ---
120  2018 ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. MM, WB
121  2018 Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. BV, PET
122  2021 A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts. CDR, GPC3, HCC, NSG, PDX, ROI